Wesley Blackaby

Wesley Blackaby

Company: Storm Therapeutics

Job title: Vice President of Chemistry

Seminars:

Live Panel Q&A – Ask the Speakers your Burning Questions 12:10 pm

Read more

day: Day Two

Targeting Cancer with First-in-class Inhibitors of the RNA m6A Methyltransferase METTL3 11:30 am

• Introduction to RNA modifications, the role of METTL3 and the m6A modification on selected mRNA species • Overview of our drug discovery efforts to identify potent and selective inhibitors of METTL3 • Characterisation of potent, selective, bioavailable inhibitors of METTL3 in biochemical, biophysical and cellular assays • Exploration of utility of METTL3 inhibitors in…Read more

day: Day Two

© Copyright 2018 Hanson Wade | Design and site by Event Engine | Hanson Wade Limited is registered in England & Wales, number 06752216.
Registered Office: Suite A, 6 Honduras Street, London EC1Y 0TH.